|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/727 | |
| A61K 35/16 | |||
| A61K 38/57 | |||
| A61P 7/02 | |||
| A61P 1/00 | |||
| A61P 11/08 | |||
| A61P 9/06 | |||
| A61P 9/12 |
| (11) | Patento numeris | 2522354 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11165869.6 |
| Europos patento paraiškos padavimo data | 2011-05-12 | |
| (97) | Europos patento paraiškos paskelbimo data | 2012-11-14 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-08-23 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (72) |
Schulte, Stefan, DE
Kalina, Uwe, DE
Moses, Michael, DE
Feussner, Annette, DE
|
| (73) |
CSL Behring GmbH,
Emil-von-Behring-Strasse 76, 35041 Marburg,
DE
|
| (54) | Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins |
| Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins |